IRAP Inhibitors Block Cytokine Export from Golgi
Solution Overview
Problem
Current therapies fail to effectively target and control the secretion of pro-inflammatory cytokines, such as TNF-α and IL-6, in mast cells, which are key contributors to inflammatory diseases, highlighting the need for a more precise mechanism to regulate their secretion and reduce inflammation.
Innovation Solution
The use of IRAP inhibitors, which target the insulin-regulated aminopeptidase (IRAP) endosomes, disrupts the secretion of pro-inflammatory cytokines by reducing their export from the Golgi apparatus and altering the localization of VAMP3+ endosomes, thereby reducing cytokine secretion and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current therapies are used to treat inflammatory diseases, then general anti-inflammatory effects are achieved, but they fail to effectively target and control the secretion of pro-inflammatory cytokines in mast cells
Solution Approach 1:
The patent introduces IRAP (insulin-regulated aminopeptidase) as an intermediary target in the secretory pathway of mast cells. By inhibiting IRAP, the therapy indirectly controls cytokine secretion without directly targeting the cytokines themselves, achieving both precision and reliability in controlling inflammatory responses
Solution Approach 2:
The patent replaces direct mechanical/targeted intervention on cytokine secretion mechanisms with a biochemical approach using IRAP inhibitors. This substitution allows for more precise control by targeting a specific enzyme in the secretory pathway rather than using broad anti-inflammatory mechanisms
2Object-generated harmful factors
If IRAP inhibitors are used to block cytokine secretion, then pro-inflammatory cytokine levels are reduced, but the mechanism involves complex interactions with endosomal trafficking and SNARE proteins
Solution Approach 1:
The patent extracts and targets a specific component (IRAP) from the complex cytokine secretion machinery. By focusing on this single enzyme rather than the entire secretory pathway, the therapy simplifies the intervention point while effectively reducing harmful cytokine secretion
Solution Approach 2:
The patent changes the parameter being targeted from the final cytokine product to an upstream enzyme (IRAP) in the secretory pathway. This parameter change allows for earlier intervention in the secretion process, reducing cytokine levels while the complex mechanistic interactions are harnessed rather than avoided
Data Source
AI summary
Upon activation, mast cells rapidly release preformed inflammatory mediators from large cytoplasmic granules via regulated exocytosis. This acute degranulation is followed by a late activation phase involving synthesis and secretion of cytokines, growth factors and other inflammatory molecules via the constitutive pathway that remains ill-defined. Here the inventors describe a role for an insulin-responsive vesicle-like endosomal compartment, marked by insulin-regulated aminopeptidase (IRAP), in the secretion of TNF-α and IL-6 in mast cells and macrophages. IRAP-deficient mice are protected from TNF-dependent kidney injury and inflammatory arthritis. In the absence of IRAP, TNF fails to be efficiently exported from the Golgi. Chemical targeting of IRAP+ endosomes reduced pro-inflammatory cytokine secretion thereby highlighting this compartment as a promising target for the therapeutic control of inflammation. Thus the present invention relates to the use of IRAP inhibitors for the treatment of inflammatory diseases